Inhaled biologics present exciting new opportunities.

In this video, TTP’s Ben Hatton, Project Lead, and Svilen Savov, Head of Respiratory, explore the potential advantages, including local targeting, mucosal immunity, and rapid systemic delivery.

However, making inhaled biologics a reality requires overcoming the tightly interwoven challenges of device design, formulation stability, and aerosolization technology. Ben and Svilen delve into these complexities, highlighting the importance of remaining device agnostic, innovating only where necessary, and minimising risks through seamless integration of formulation and device engineering teams.

свернуть